Surrozen (SRZN) Cash from Operations Growth (1y) (2021 - 2026)
Surrozen (SRZN) Cash from Operations Growth (1y) (2021 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
788,338.31 Bn |
788,338.28 Bn |
- |
- |
| 2 |
Belite Bio |
56,560.00 Bn |
56,560.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
17,329.30 Bn |
17,329.30 Bn |
- |
60.84% |
| 4 |
Legend Biotech |
3,341.00 Bn |
3,340.71 Bn |
242.10 Mn |
85.14% |
| 5 |
Akari Therapeutics |
1,727.91 Bn |
1,727.91 Bn |
- |
-15.72% |
| 6 |
Evaxion A |
1,536.68 Bn |
1,536.67 Bn |
- |
- |
| 7 |
Psyence Biomedical |
238.34 Bn |
238.33 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.42 Bn |
106.17 Bn |
2.59 Bn |
74.39% |
| 9 |
Abivax |
95.45 Bn |
95.45 Bn |
- |
- |
| 10 |
Surrozen |
239,016.67 |
-106.67 Mn |
- |
-34.35% |
| Date | Value |
|---|
| Mar 31, 2026 |
-34.35% |
| Dec 31, 2025 |
-266.54% |
| Sep 30, 2025 |
-33.29% |
| Jun 30, 2025 |
-7.83% |
| Mar 31, 2025 |
-6.90% |
| Dec 31, 2024 |
148.07% |
| Sep 30, 2024 |
33.68% |
| Jun 30, 2024 |
35.34% |
| Mar 31, 2024 |
38.60% |
| Dec 31, 2023 |
-4,462.50% |
| Sep 30, 2023 |
28.06% |
| Jun 30, 2023 |
23.17% |
| Mar 31, 2023 |
22.99% |
| Dec 31, 2022 |
98.61% |
| Sep 30, 2022 |
-0.68% |
| Jun 30, 2022 |
11.59% |
| Mar 31, 2022 |
-78.09% |
| Dec 31, 2021 |
-1,134.49% |
